A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Trial Profile

A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Ofranergene obadenovec (Primary)
  • Indications Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OVAL
  • Sponsors VBL Therapeutics
  • Most Recent Events

    • 15 Mar 2018 According to a VBL Therapeutics media release, company expect the interim readout may be available during the first half of 2019.
    • 27 Dec 2017 According to a VBL Therapeutics media release, the first patient has been enrolled in this trial that will be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation.
    • 27 Dec 2017 Status changed from planning to recruiting according to a VBL Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top